Tirzepatideni agashya kabili agonist ya reseptor ya GIP na GLP-1, yemerewe kugenzura glycemic kubantu bakuze barwaye diyabete yo mu bwoko bwa 2 kimwe no gucunga ibiro birebire kubantu bafite indangagaciro z'umubiri (BMI) kg30 kg / m², cyangwa ≥27 kg / m² byibuze byibuze kimwe kijyanye n'uburemere.
Kuri diyabete, igabanya glucose no kwiyiriza ubusa nyuma yo gutinda gusiba gastric, kongera imisemburo ya insuline iterwa na glucose, no guhagarika irekurwa rya glucagon, ifite ibyago bike byo kurwara hypoglycemia ugereranije n’ibanga rya insuline gakondo. Mu micungire y’umubyibuho ukabije, ibikorwa byayo byombi hagati na peripheri bigabanya ubushake bwo kurya no kongera ingufu zikoreshwa. Igeragezwa rya Clinical ryerekanye ko ibyumweru 52-72 byo kuvura bishobora kugera ku kigereranyo cyo kugabanya ibiro 15% - 20%, bikajyana no kunoza umuzenguruko, umuvuduko wamaraso, na triglyceride.
Ibintu bibi bikunze kugaragara ni ibimenyetso byigifu byoroheje kandi bitagereranywa, bikunze kugaragara mubyumweru bike byambere bikagabanywa no kwiyongera kwa dose gahoro gahoro. Gutangiza amavuriro birasabwa gusuzumwa na endocrinologue cyangwa inzobere mu gucunga ibiro, hamwe nogukurikirana glucose, uburemere bwumubiri, nimikorere yimpyiko. Muri rusange, tirzepatide itanga ibimenyetso bifatika, bifite umutekano, kandi birambye byo kuvura abarwayi bakeneye glycemic ndetse no kugenzura ibiro.
Igihe cyo kohereza: Kanama-27-2025